Treatments, not prevention, dominate diabetes research

April 5, 2013

Research for diabetes is far more focused on drug therapies than preventive measures, and tends to exclude children and older people who have much to gain from better disease management, according to a Duke Medicine study.

By analyzing nearly 2,500 diabetes-related registered in ClinicalTrials.gov from 2007-10, the authors provide a broad overview of the for diabetes. The effort is part of the Clinical Trials Transformation Initiative, a public-private partnership founded by the U.S. (FDA) and Duke University to identify and promote practices to improve clinical trials.

The findings, published April 5, 2013, in the journal Diabetologia, suggest that current research efforts may not adequately address , management or therapeutic safety.

"It's important that clinical trials enroll patients who are representative of populations affected by diabetes and its complications," said Jennifer Green, M.D, associate professor at Duke University School of Medicine and member of the Duke Clinical Research Institute. "Our study is just a snapshot in time, but it can serve as a guide for where we need to focus attention and resources."

Green and colleagues culled data from the clinical trials website for studies aimed at diabetes or conditions related to diabetes. ClinicalTrials.gov, a collaboration between the National Institutes of Health and the FDA, is a registry of trials conducted in the United States and 174 other countries.

Of 2,484 trials related to diabetes identified by the researchers, 75 percent focused on diabetes treatment, while 10 percent were designed to test a preventive measure. Most of the interventions – 63 percent – involved a drug, while 12 percent were behavioral.

"We don't know what the right ratio of these different types of trials should be, but this is a good starting point for discussion," Green said.

The researchers also found that most enrolled small numbers of patients at a limited number of sites, were completed in less than two years, and did not represent a geographically broad mix of patients.

Type 2 diabetes generally develops among adults, with older adults being at greatest risk. Diabetes rates are also increasing among children and adolescents, particularly those living in wealthier nations.

According to the research group, older people were explicitly excluded from 31 percent of trials, and were the main focus of only 1 percent of the studies. Similarly, just 4 percent of diabetes trials were aimed at people ages 18 and younger.

"When trials are excluding patients who are older or younger, it's questionable whether the trial findings can be applied to people in those age groups," Green said. "We really don't understand how best to manage disease in these patients – particularly among patients of advanced age. So the exclusion of them from most studies and the small number of trials that specifically enroll older individuals is problematic."

The research group also found that only small numbers of diabetes trials were designed to assess the effect of interventions upon events such as heart attack, stroke, or death.

"We will see many more such trials in the future, given the recent emphasis on assessing medications for cardiovascular safety," Green said.

Explore further: Children continue to be underrepresented in drug trials

Related Stories

Children continue to be underrepresented in drug trials

July 23, 2012
(HealthDay) -- Even for conditions with a high pediatric disease burden, only a small proportion of clinical drug trials study pediatric patients, according to research published online July 23 in Pediatrics.

Older adults with diabetes live long enough to benefit from interventions

May 2, 2012
Middle-aged and older adults with diabetes showed substantial survival rates in a new University of Michigan Health System study of retirees.

Children underrepresented in drug studies, researchers say

October 1, 2012
The number of clinical trials enrolling children is far lower than for adults, and the scope of research is also narrower, according to an analysis of public-access data conducted by researchers at Duke University.

Intensive-dose statin therapy associated with increased risk of diabetes

June 21, 2011
An analysis of data from previously published studies indicates that intensive-dose statin therapy is associated with an increased risk of new-onset diabetes compared with moderate-dose therapy, according to a study in the ...

Income affects oncology clinical trial participation

January 16, 2013
(HealthDay)—Oncology patients with lower income, even older patients with access to Medicare, are significantly less likely to participate in clinical trials, according to research published online Jan. 7 in the Journal ...

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.